Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate whether MM09, a sublingual immunotherapy, can help patients aged 12 to 65 with moderate-to-severe allergic rhinitis or rhinoconjunctivitis caused by house dust mites, with or without mild to moderate asthma. The trial is a phase III, randomized, double-blind, placebo-controlled study designed to assess if MM09 reduces symptoms and the need for rescue medications, while also monitoring safety. Participants will receive either the active MM09 sublingual spray or a placebo solution without the active ingredient. The treatment is given daily over 12 months. The study carefully compares the effects of MM09 against placebo to understand its impact on allergic rhinitisrhinoconjunctivitis and asthma symptoms. During the study, participants will record symptoms and medication use via a smartphone app. Researchers will measure combined symptom and medication scores, as well as separate scores for rhinitis, rhinoconjunctivitis, and asthma symptoms and medication intake during the last four weeks of treatment. Safety and any medical problems from inhaling MM09 will be closely monitored throughout the trial, which lasts up to 12 months.
Actively Recruiting
Scientific research has shown that staying active during pregnancy can help prevent and manage complications like gestational diabetes, hypertension, obesity, and improve overall fitness, mental health, and postpartum recovery. However, many pregnant and postpartum women lack proper guidance on exercising safely, and inactivity remains common. This research evaluates the benefits of a supervised prenatal exercise program delivered either in person or online, aiming to improve maternal physical activity, fitness, and healthy lifestyle behaviors. The study offers a 12-week multicomponent exercise program, including aerobic, coordination, strength, postural, stretching, and pelvic floor exercises. Participants attend two 60-minute sessions weekly, supervised by qualified exercise physiologists. Women join either an in-person group at healthcare, university, or fitness centers or an online group exercising at home or outdoors. The program follows international guidelines and includes access to additional free resources like the Active Pregnancy Guide and YouTube workouts. Participants complete validated questionnaires and fitness tests before and after the 12-week intervention to assess physical activity, fitness, sleep, diet, stress, and other health factors. Researchers will compare the effects of in-person versus online exercise on these outcomes and gather participant feedback on satisfaction and resource use. All participation and resources are free, and the study aims to inform future exercise recommendations and public health strategies for pregnant women.
Actively Recruiting
Researchers are evaluating the long-term reliability and performance of cardiac rhythm products marketed by Medtronic. This observational study focuses on devices such as leads, implantable pulse generators, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices used for conditions like arrhythmia, bradycardia, heart failure, and sinus tachycardia. The study aims to analyze product survival probabilities and monitor lead-related complications over time. Participants include individuals who have received or will receive Medtronic market-released cardiac devices for pacing, sensing, or defibrillation. The study includes products implanted as part of routine care or participants from prior qualifying studies. Data is collected from the time of implantation and continues until the device is removed from service, the patient exits the study, or passes away. Enrollment criteria also require consent for access to health information. During the study, participants device performance is monitored through follow-up data collection. Researchers assess complications related to the implanted leads and track device status over long periods, potentially spanning several years. The study does not involve additional treatments but relies on routine clinical follow-up and health information review. The total duration extends up to December 2040, allowing comprehensive long-term evaluation of device performance.
Actively Recruiting
This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.
Actively Recruiting
Researchers are evaluating whether EP-088MM09, which contains modified house dust mite allergens called mannan-conjugated allergoids, can treat house dust mite allergy. This Phase 3 clinical trial involves 250 participants aged 12 to 65 years with persistent moderate to severe nasal allergy symptoms, with or without eye symptoms, and possibly mild or moderate controlled allergic asthma. The study aims to compare the treatments effect on allergy symptoms and the need for relief medicines against a placebo while assessing safety. Participants will be randomly assigned to receive either EP-088MM09 or a placebo, both given as subcutaneous injections. The treatment phase includes 12 monthly visits where participants receive injections under the skin the first visit involves two injections, and subsequent visits involve one injection each. Some participants sensitive to pollen may have an additional baseline visit to ensure symptom assessments avoid pollen season influence. After completing treatment, a final follow-up visit occurs about one month later. Throughout the study, participants will attend screening visits to confirm eligibility, complete daily symptom and medication diaries during specified periods, and provide blood samples and questionnaires on symptoms and quality of life. Clinic visits include monitoring of health and medication use, with participants staying at the clinic for at least 30 minutes after each injection. The main outcome measured is a combined score of symptoms and medication use over four weeks following treatment. Participation lasts approximately 14 to 21 months.